Last updated 8 days ago
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
7140 patients around the world
Available in Argentina, Mexico, Brazil, Belgium, Spain, Colombia
Eli Lilly and Company
106Research sites
7140Patients around the world
This study is for people with
Cardiovascular disease
Renal disease
Chronic kidney disease
Requirements for the patient
From 50 Years
All Gender
Medical requirements
- Have established ASCVD and/or CKD.
- Have type 1 diabetes.Have had a major heart condition within 60 days prior to screening.Have New York Heart Association Functional Classification Class IV heart failure.
Sites
CEDIMBA - DIM Clínica Privada - Buenos Aires
Recruiting
Instituto de Investigaciones Clínicas Tucumán
Recruiting
Centro de Investigaciones Clínicas Baigorria
Recruiting
Instituto Médico de la Fundación Estudios Clínicos - Rosario
Recruiting
Centro de Investigaciones Médicas Tucumán
Recruiting
Centro Médico Maffei - CABA, Buenos Aires
Recruiting
Centro Médico Viamonte SRL - CABA, Buenos Aires
Recruiting
Hospital Provincial del Centenario - Rosario, Santa Fe
Recruiting
Centro de Investigaciones Clínicas - IESR - Rosario, Santa Fe
Recruiting
Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Médica - Rosario, Santa Fe
Recruiting
StudyATTAIN-Outcomes
SponsorEli Lilly and Company
Study typeInterventional
Conditions
Cardiovascular diseaseChronic kidney disease
Requirements
From 50 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07241390
